 Dr. Reddys Laboratories Ltd NYSE: RDY has initiated the process with the Drugs Controller General of India for Emergency Use Authorization EUA of the human adenoviral vector-based platform COVID-19 vaccine candidate, Sputnik V. As part of the review process, Dr. Reddys will present the Phase 2 studys safety profile and interim data of the phase 3 study, which is expected to complete by February 21. 